[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367145-105":59,"doc-detail-367145-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","serological-and-molecular-detection-of-toxoplasma-gondii-among-cancer-patients-in-sohag-upper-egypt-a-case-control-study","Serological and molecular detection of Toxoplasma Gondii among cancer patients in Sohag, Upper Egypt: a case-control study","","Study of Toxoplasma gondii infection in cancer patients in Sohag, Upper Egypt using serology and molecular assays. Sera from 50 chemotherapy-treated cancer patients and 50 matched healthy controls were tested for IgG and IgM. Buffy coats were analyzed by conventional and nested PCR targeting B1 and RE genes. Cancer patients showed high overall IgG seroprevalence (58% overall; IgG 30%, IgM 9%). Solid tumors had higher IgG positivity than hematologic tumors (77.27% vs 46.43%; P=0.03), while only 4 (9%) were PCR-positive in both assays. PCR is recommended to complement serology for acute or reactivated toxoplasmosis.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/serological-and-molecular-detection-of-toxoplasma-gondii-among-cancer-patients-in-sohag-upper-egypt-a-case-control-study/367145/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/serological-and-molecular-detection-of-toxoplasma-gondii-among-cancer-patients-in-sohag-upper-egypt-a-case-control-study/367145.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What diagnostic methods were used in the study?","Question",{"text":112,"@type":113},"The study used serological testing for Toxoplasma IgG and IgM and molecular detection using conventional and nested PCR targeting B1 and RE genes on buffy coats.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were cancer patients selected and categorized?",{"text":117,"@type":113},"Fifty cancer patients on chemotherapy were recruited and categorized into solid organ malignancies and hematologic malignancies. Participants with prior anti-Toxoplasma therapy were excluded.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings on seroprevalence and PCR detection?",{"text":121,"@type":113},"Overall IgG seroprevalence was high (58%), with IgG and IgM detected in 30% and 9% of cancer patients, respectively. Only 4 (9%) were positive on both PCR assays, and solid cancer patients had higher IgG positivity than hematologic tumor patients (P=0.03).",{"name":123,"@type":110,"acceptedAnswer":124},"Why is PCR recommended for cancer patients in this context?",{"text":125,"@type":113},"PCR was recommended to complement serology because it helps diagnose acute or reactivated toxoplasmosis, which is particularly important for immunocompromised cancer patients.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},367145,1790785325,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nSerological and molecular detection of Toxoplasma Gondii among cancer patients in Sohag, Upper Egypt: a case-control study  \nEman Fathi Fadel1􀀍, Mohammed Essa Marghany Tolba2, Amal Mostafa Ahmed1 & Hanaa Ahmed EL-Hady1  \nToxoplasma gondii (T. gondii) affects around 30% of humans worldwide. Recently, it has emerged asa significant opportunistic pathogen to immunocompromised patients. Data available is still lacking about toxoplasmosis in cancer patients in Egypt. This study aimed to reveal the current trend of  \nT. gondii in cancer patients in Sohag, Egypt. Sera from 50 cancer patients and 50 healthy controls were screened for Toxoplasma IgG and IgM. Further, buffy coats from both groups were used for detection of T. gondii B1 and RE genes via conventional and nested PCR, respectively. The overallseroprevalence of T. gondii IgG was high (58%) . IgG and IgM were detected in 30% and 9% cancer patients, respectively. Patients with solid cancers exhibited a greater IgG seropositivity compared to those with hematologic tumors (77.27% and 46.43%, respectively) (P = 0.03). Concerning the molecular results, only 4 (9%) were positive regarding both PCR assays. In conclusion, T. gondii is highly prevalent in cancer patients in Sohag, Egypt. PCR is strongly recommended to complement serology to diagnose acute or reactivated toxoplasmosis in cancer patients. B1 PCR was found to be equivalent to RE PCR. Nevertheless, thorough large-scale research must be implemented.  \nKeywords Toxoplasma Gondii, Serology, Molecular, Cancer patients, Egypt  \nToxoplasma gondii ( T. gondii) is an intracellular protozoan parasite that can infect any nucleated vertebrate cells. It affects 30–65% of the human population worldwide1,2. Humans become primarily infected by ingesting raw or undercooked meat containing viable tissue cysts, or by ingesting water or food contaminated with oocysts from infected cat feces3. The primary infection in immunocompetent individuals is typically either asymptomatic or oligosymptomatic with lymphadenopathy and flu-like symptoms, depending on host susceptibility and the virulence of the strain4,5. T. gondii has recently emerged as a significant opportunistic pathogen that poses alife-threatening risk to immunocompromised patients. Cancer patients are exposed to a risk of reactivating a latent infection as a result of deficient cellular immunity or antineoplastic drugs. Cancer chemotherapy induces profound and persistent CD4 T cells depletion6. T. gondii disseminates through the host body with using the Trojan horse strategy, it can even enter immune-privileged sites resulting in toxoplasmic chorioretinitis and encephalitis following reactivation7. Thus, effective, rapid and accurate diagnosis is crucial and desirable to initiate adequate treatment and to achieve good prognosis8. The diagnosis of T. gondii infection continues tobe a major challenge. Currently, serological diagnosis plays a crucial role in the diagnosis of T. gondii human infections9. Despite the innovations in serologic methods, there are still intractable limitations including the inability to confirm the existence of the parasite in immunocompromised patients10. To tackle these constraints, a variety of molecular assays such as conventional, nested, real-time PCR (qPCR) and loop-mediated isothermal amplification (LAMP) have been developed to detect T. gondii DNA in different biological samples11. Since molecular diagnosis is not influenced by the immunologic status of the patient, it is postulated to be the best option for cancer patients12. Moreover, molecular methods can efficiently detect Toxoplasma in fluids or tissues as it typically circulates at low concentrations, or inconstantly13. Very few reports are available about toxoplasmosisin cancer patients14. This study aimed to reveal the current trend of T. gondii in cancer patients utilizing serologic and molecular diagnostic met","cbCaia2SptdmhQBz","https://ap.wps.com/l/cbCaia2SptdmhQBz","pdf",1927461,14,"English","# Methods\n## Study design","[{\"question\":\"What diagnostic methods were used in the study?\",\"answer\":\"The study used serological testing for Toxoplasma IgG and IgM and molecular detection using conventional and nested PCR targeting B1 and RE genes on buffy coats.\"},{\"question\":\"How were cancer patients selected and categorized?\",\"answer\":\"Fifty cancer patients on chemotherapy were recruited and categorized into solid organ malignancies and hematologic malignancies. Participants with prior anti-Toxoplasma therapy were excluded.\"},{\"question\":\"What were the main findings on seroprevalence and PCR detection?\",\"answer\":\"Overall IgG seroprevalence was high (58%), with IgG and IgM detected in 30% and 9% of cancer patients, respectively. Only 4 (9%) were positive on both PCR assays, and solid cancer patients had higher IgG positivity than hematologic tumor patients (P=0.03).\"},{\"question\":\"Why is PCR recommended for cancer patients in this context?\",\"answer\":\"PCR was recommended to complement serology because it helps diagnose acute or reactivated toxoplasmosis, which is particularly important for immunocompromised cancer patients.\"}]","Serological and molecular detection of Toxoplasma Gondii among cancer patients in Sohag, Upper Egypt: a case-control study | PDF",1790169465,35,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7977b85595f5cc08796a3f6787d129d0.webp",983,1291,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/467cdf0a68f8ae300fb8afea7f0911bb.webp",982,1290,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/349916eb21dfaa0655de1c96e87202cd.webp",981,1289,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/755ff0052cdcce4b910d0f8b493afd73.webp",980,1287]